OTCMMBCOF
Market cap4mUSD
Jan 10, Last price
0.10USD
1D
4.62%
1Q
2.00%
IPO
49.56%
Name
Marvel Biosciences Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-2m
L-10.29%
CFO
-1m
L-11.46%
Profile
Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑07 | 2023‑07 | 2022‑07 | 2021‑07 | 2020‑07 | 2019‑07 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 3,184 | 3,873 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (3,184) | (3,873) | ||||
NOPBT Margin | ||||||
Operating Taxes | 6 | |||||
Tax Rate | ||||||
NOPAT | (3,184) | (3,878) | ||||
Net income | (2,291) -10.29% | (2,554) -15.96% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 500 | 270 | 420 | |||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | 1,710 | 1,000 | ||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | 1,364 | 443 | (593) | |||
| Cash flow | ||||||
Cash from operating activities | (1,179) | (1,332) | (2,194) | |||
CAPEX | 5 | |||||
Cash from investing activities | ||||||
Cash from financing activities | 969 | 1,296 | 394 | |||
FCF | 396 | (2,464) | (3,878) | |||
| Balance | ||||||
Cash | 346 | 557 | 593 | |||
Long term investments | ||||||
Excess cash | 346 | 557 | 593 | |||
Stockholders' equity | (3,120) | (1,922) | 104 | |||
Invested Capital | 2,005 | 1,202 | 92 | |||
ROIC | ||||||
ROCE | 442.14% | |||||
| EV | ||||||
Common stock shares outstanding | 39,660 | 32,759 | ||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | (3,184) | (3,872) | ||||
EV/EBITDA | ||||||
Interest | 35 | 2 | ||||
Interest/NOPBT | ||||||